Cargando…
Feasibility of a fast-track randomized controlled trial of cell-free and concentrated ascites reinfusion therapy for patients with refractory malignant ascites
BACKGROUND: Malignant ascites often causes discomfort in advanced cancer patients. Paracentesis is the most common treatment modality, but it requires frequently repeated treatment. Cell-free and concentrated ascites reinfusion therapy (CART) may prolong the paracentesis interval, but controlled tri...
Autores principales: | Yokomichi, Naosuke, Imai, Kengo, Sakamoto, Masaki, Horiki, Masashi, Yamauchi, Toshihiro, Miwa, Satoru, Inoue, Satoshi, Uneno, Yu, Suzuki, Hidekazu, Wada, Toru, Ichikawa, Yuri, Morita, Tatsuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883725/ https://www.ncbi.nlm.nih.gov/pubmed/35227250 http://dx.doi.org/10.1186/s12885-022-09336-3 |
Ejemplares similares
-
Weaning from concentrated ascites reinfusion therapy for refractory ascites by SGLT2 inhibitor
por: Miyamoto, Yasunori, et al.
Publicado: (2021) -
Reinfusion of ascites during hemodialysis as a treatment of massive refractory ascites and acute renal failure
por: Hsu, Ta-Wei, et al.
Publicado: (2011) -
Ascites reinfusion dialysis of refractory ascites as a bridge to kidney and liver transplantation in a patient on hemodialysis
por: Chang, Kyung Yoon, et al.
Publicado: (2017) -
Effectiveness of Cell-Free and Concentrated Ascites Reinfusion Therapy in the Treatment of Malignancy-Related Ascites: A Systematic Review and Meta-Analysis
por: Chen, Hao, et al.
Publicado: (2021) -
Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan
por: Iwasa, Motoh, et al.
Publicado: (2019)